Share This Author
A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
- D. Tashkin, B. Celli, M. Decramer
- Medicine, PsychologyThe New England journal of medicine
- 9 October 2008
Therapy with tiotropium was associated with improvements in lung function, quality of life, and exacerbations during a 4-year period but did not significantly reduce the rate of decline in FEV(1).
Cyclophosphamide versus placebo in scleroderma lung disease.
One year of oral cyclophosphamide in patients with symptomatic scleroderma-related interstitial lung disease had a significant but modest beneficial effect on lung function, dyspnea, thickening of the skin, and the health-related quality of life.
A placebo-controlled, randomized trial of mesenchymal stem cells in COPD.
- D. Weiss, R. Casaburi, Robin L. Flannery, Michelle LeRoux-Williams, D. Tashkin
- 1 June 2013
Systemic MSC administration appears to be safe in patients with moderate to severe COPD and provides a basis for subsequent cell therapy investigations.
Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial
Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1
An aggressive smoking intervention program significantly reduces the age-related decline in FEV 1 in middle-aged smokers with mild airways obstruction and use of an inhaled anticholinergic bronchodilator results in a relatively small improvement inFEV 1 that appears to be reversed after the drug is discontinued.
Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial
C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease
CRP measurements provide incremental prognostic information beyond that achieved by traditional markers of prognosis in patients with mild to moderate COPD, and may enable more accurate detection of patients at a high risk of mortality.
Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic
It is demonstrated, as proof of concept, that 3′AmNic‐rEPA elicits Abs to nicotine and is associated with higher continuous abstinence rates (CAR) and its further development as a treatment for nicotine dependence is justified.
Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
The existing data for LAMA/LABA combinations in the treatment of COPD is outlined, the ongoing trials are summarized, and the evidence required to inform the role of LAMA-LABA combination in treatment of this disease is considered.
Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small cell lung cancer.
The majority of long-term survivors of non-small cell lung cancer experienced respiratory symptoms, and more than one third reported dyspnea, including one of five patients with seriously diminished pulmonary function.